All articles
Can Ozempic® Cause Diarrhea: Exploring Side Effects & Management
Reading time:
5 min
Weight loss
Get expert guidance and a personalized care plan designed around you.
Comparing Diarrhea in Ozempic® with Other Medications for Weight Loss
Understanding the side effect profile is crucial when choosing the right medication for diabetes management or weight loss. Ozempic® is not the only medication taken for weight loss that causes diarrhea.
Gastrointestinal disturbances, including diarrhea, are a well-known and common side effect of all GLP-1 medications approved for diabetes and weight loss (11). However, the benefits of glycemic control and weight reduction must be weighed against the risk of side effects. Each medication in this class has a unique profile, and responses can vary greatly among individuals. Explore other medications here: https://joinmochi.com/medications
In conclusion, diarrhea is a common side effect of Ozempic® and represents a potential barrier to its use, especially at higher doses. However, there are strategies to manage diarrhea, and your healthcare provider can work with you to optimize your medication regimen. As always, it's best to discuss your concerns with a healthcare provider to ensure the benefits of using Ozempic® outweigh any side effects.
Get Tailored Support Managing Your Ozempic® Treatment
If you're considering Ozempic® for weight management, it's essential to have a knowledgeable and trustworthy care team by your side. Joining Mochi Health's weight care program can provide invaluable resources and personalized strategies to maximize results and mitigate side effects while on Ozempic®. Our healthcare providers are well-versed in managing side effects, including diarrhea, and can work with you to tailor your treatment plan based on your individual needs. Through thorough communication and ongoing support, we aim to ensure that you not only navigate the challenges of weight loss but also achieve lasting success. Embrace a healthier lifestyle today—take the first step and find out if you’re eligible for our program today.
References:
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989–1002. https://www.nejm.org/doi/10.1056/NEJMoa2032183?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020 Mar 26;5(6). https://insight.jci.org/articles/view/133429
Weber MM. Trust the Gold Standard: All Glucagon-like Peptide-1 Receptor Agonists Can Delay Gastric Emptying. Anesthesiology. 2024 Jan 1;140(1):178–80. https://pubmed.ncbi.nlm.nih.gov/37934577/
Horowitz M, Wishart JM, Jones KL, Hebbard GS. Gastric emptying in diabetes: an overview. Diabet Med. 1996 Sep;13(9 Suppl 5):S16-22. https://pubmed.ncbi.nlm.nih.gov/8894465/
Banks KP, Syed K, Parekh M, et al. Gastric Emptying Scan. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531503/
Kato, S., Sato, T., Fujita, H. et al. Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms. Sci Rep 11, 9167 (2021). https://www.nature.com/articles/s41598-021-88612-x
Fass, R., McCallum, R. W., & Parkman, H. P. (2009). Treatment Challenges in the Management of Gastroparesis-Related GERD. Gastroenterology & hepatology, 5(10 Suppl 18), 4–16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886367/
Avery, M. E., & Snyder, J. D. (1990). Oral therapy for acute diarrhea. The underused simple solution. The New England journal of medicine, 323(13), 891–894. https://www.nejm.org/doi/10.1056/NEJM199009273231307?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Duggan, C., Santosham, M., & Glass, R. I. (1992). The management of acute diarrhea in children: oral rehydration, maintenance, and nutritional therapy. Centers for Disease Control and Prevention. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 41(RR-16), 1–20. https://www.cdc.gov/mmwr/preview/mmwrhtml/00018677.htm
Riddle, M. S., DuPont, H. L., & Connor, B. A. (2016). ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. The American journal of gastroenterology, 111(5), 602–622. https://journals.lww.com/ajg/fulltext/2016/05000/acg_clinical_guideline__diagnosis,_treatment,_and.14.aspx
Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022). Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, 134(1), 14–19. https://www.tandfonline.com/doi/full/10.1080/00325481.2021.2002616
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles
Read next
For iOS & Android
